Edition:
United Kingdom

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

2.28USD
21 Sep 2018
Change (% chg)

$-0.04 (-1.72%)
Prev Close
$2.32
Open
$2.38
Day's High
$2.38
Day's Low
$2.25
Volume
9,773
Avg. Vol
30,367
52-wk High
$15.75
52-wk Low
$1.97

Latest Key Developments (Source: Significant Developments)

Summit Therapeutics enters exclusive licence agreement with Eurofarma Laboratórios
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Summit Therapeutics Plc ::SUMMIT THERAPEUTICS PLC HAS ENTERED INTO AN EXCLUSIVE LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA LABORATÓRIOS SA.AGREEMENT GRANTS EUROFARMA LABORATÓRIOS SA RIGHTS IN LATIN AMERICA TO SUMMIT'S PRECISION ANTIBIOTIC RIDINILAZOLE IN DEVELOPMENT FOR THE TREATMENT OF CDI.SUMMIT RETAINS COMMERCIALISATION RIGHTS IN ALL OTHER COUNTRIES.RIDINILAZOLE IS A TARGETED ANTIBIOTIC THAT HAS THE POTENTIAL AS A FRONTLINE THERAPY TO TREAT INITIAL INFECTION AND PRESERVE PATIENTS' MICROBIOMES TO REDUCE THE RATE OF RECURRENT CDI .  Full Article

Summit's agreement with Sarepta also contains a standstill provision
Tuesday, 4 Oct 2016 

Summit Therapeutics Plc : Collaboration agreement with Sarepta also contains a standstill provision - SEC filing .Summit Therapeutics - Believes cash, cash equivalents, certain upfront payments from Sarepta collaboration to be sufficient to fund expenses through 2018.  Full Article

Sarepta and Summit enter into agreement for European rights to utrophin modulator pipeline
Tuesday, 4 Oct 2016 

Summit Therapeutics Plc : Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royalties . Sarepta also receives option for Latin American rights . As part of agreement, Sarepta also obtains an option to license latin american rights to Summit's utrophin modulator pipeline . If Sarepta elects to exercise option for Latin American rights, co would be entitled to additional fees, milestones and royalties . Sarepta and Summit to share research and development costs . Sarepta also receives option for Latin American rights . Sarepta Therapeutics and summit enter into exclusive license and collaboration agreement for european rights to summit’s utrophin modulator pipeline for the treatment of duchenne muscular dystrophy .Sarepta, co will share specified utrophin modulator-related research and development costs at a 45/55 pct split, respectively.  Full Article

UPDATE 1-UK Stocks-Factors to watch on Sept. 20

Sept 20 Britain's FTSE 100 futures were flat ahead of the cash market open on Thursday.

No consensus analysis data available.